Brief: Cabaletta Bio Receives FDA Fast Track Designation For CABA-201
01/05/2023 13:23
May 1 (Reuters) - Cabaletta Bio Inc CABA.O :
* CABALETTA BIO RECEIVES FDA FAST TRACK DESIGNATION FOR
CABA-201
* CABALETTA BIO RECEIVES FDA FAST TRACK DESIGNATION FOR
CABA-201
Source text for Eikon: ID:nGNX4BQ1VZ
Further company coverage: CABA.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsCabaletta Bio Q1 net loss widens as R&D costs rise
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity